Search results for " Medicina Interna"

showing 10 items of 1302 documents

Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected mediterranean subjects

2012

Abstract Background Despite the reported high prevalence of osteoporosis in the human immunodeficiency virus (HIV)-population, there have been no previous studies examining dairy calcium intake and bone mineral density (BMD) in HIV-subjects. We assessed the prevalence of low BMD in HIV-infected and uninfected subjects and analyzed the effects of calcium intake, lifestyle and HIV-related risk factors on BMD. Methods One hundred and twelve HIV-infected subjects were consecutively enrolled. Seventy- six HIV-uninfected subjects matched for age and sex were enrolled as the control group. The HIV-subjects were interviewed about lifestyle habits and completed a weekly food-frequency questionnaire …

musculoskeletal diseasesAdultMalemedicine.medical_specialtyFRAXSettore MED/09 - Medicina InternaBone densitySettore MED/17 - Malattie InfettiveOsteoporosisHIV Infectionslcsh:Infectious and parasitic diseasesBone remodelingAbsorptiometry PhotonBone DensityRisk FactorsSurveys and QuestionnairesInternal medicineVitamin D and neurologyBone mineral densityHumansMedicinelcsh:RC109-216Life StyleBone mineralMediterranean Regionbusiness.industryOsteopeniaCase-control studyOsteoporosiHIVMiddle AgedDairy intakemedicine.diseaseDietOsteopeniaInfectious DiseasesEndocrinologyCase-Control StudiesOsteoporosisCalciumFemalebusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaResearch Article
researchProduct

Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease.

2010

The treatment of moderate-to-severe steroid-dependent Crohn's disease has been a challenging issue for the gastroenterologist. Until to 10 years ago, immunosuppressors, mainly azathioprine or 6-mercaptopurine, were the best possible treatments available, and remission rates ranged from 30 to 60% according to the results of open studies and controlled trials. Recently, infliximab has been shown to be effective in steroid-dependent patients and, combined with azathioprine, it has been shown to increase 1-year remission rates. A recent large randomized controlled trial comparing infliximab, azathioprine and infliximab plus azathioprine demonstrated that the combination of infliximab plus azath…

musculoskeletal diseasesCrohn's diseasemedicine.medical_specialtySettore MED/09 - Medicina InternaHepatologyCombination therapybusiness.industryGastroenterologyAzathioprinemedicine.diseaseGastroenterologyInfliximablaw.inventionSurgeryRandomized controlled triallawInternal medicinemedicineInfliximab azathioprine Crohnbusinessmedicine.drug
researchProduct

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analy…

2018

Abstract Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in…

musculoskeletal diseasesModerate to severeAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaBiologicDisease durationAdalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies Monoclonal; Colitis Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alphaUlcerativeBiologicsGolimumabSeverity of Illness IndexTreatment failureAntibodies03 medical and health sciences0302 clinical medicineInternal medicineMonoclonalAdalimumabmedicineHumansskin and connective tissue diseasesAdalimumab; Biologics; Golimumab; Ulcerative colitis; Hepatology; GastroenterologyPropensity ScoreProportional Hazards ModelsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabAntibodies MonoclonalMiddle Agedmedicine.diseaseColitisUlcerative colitishumanitiesGolimumabLogistic ModelsTreatment OutcomeUlcerative colitisItaly030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessmedicine.drug
researchProduct

Una nuova strategia ipocolesterolemizzante: ruolo del peptide EGF-A nell’inibizione in vitro dell’attività catalitica del mutante PCSK9-D374Y

2011

mutante PCSK9-D374Ypeptide EGF-ASettore MED/09 - Medicina Internaipocolesterolemizzante
researchProduct

EVALUATING THE RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: IS THE SERUM HEPATITIS B PROFILE RELIABLE?

2009

Background/Aim: Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosuppression are potentially at risk of HBV reactivation. In order to assess whether a polymerase chain reaction (PCR) assay for HBV DNA in serum could be used to predict the reactivation of an occult HBV infection, we performed a retrospective study in a cohort of Sicilian patients with oncohaematological diseases. Methods: We studied by a highly sensitive ad hoc nested PCR for serum HBV DNA 75 HBsAg-negative oncohaematological patients requiring chemotherapy. Results: Thirty-three patients (44%) were HBV seronegative (anti-HBc and anti-HBs negative) and 42 patients (56%) were HBV seropositive (a…

nested PCRSettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/12 - GastroenterologiaIMMUNOSUPPRESSIONSettore MED/09 - Medicina InternaHBsAg SEROREVERSIONOBI
researchProduct

OSTEOPOROSI MASCHILE: UN CASO DI PARAPARESI CONSEGUENTE A MIELOPATIA DORSALE DA FRATTURA VERTEBRALE SEVERA

2009

osteoporosi maschile frattureSettore MED/09 - Medicina Interna
researchProduct

OSTEOPOROSI NELL’ANZIANO: UPDATE SULLE TERAPIE FARMACOLOGICHE E NON FARMACOLOGICHE

2010

osteoporosi anziano vitamina d calcio bisfosfonati teriparatide ranelato di stronzioSettore MED/09 - Medicina Interna
researchProduct

L'osteoporosi e le fratture da fragilità: una nuova sindrome geriatrica?

2012

osteoporosi fratture fragilità invecchiamento frattura femoreSettore MED/09 - Medicina Interna
researchProduct

Liver disease severity and low bone mineral density in HIV mono-infected and HIV/HCV co-infected patients

2014

Background: In this study we assess: prevalence of osteopenia, osteoporosis and reduced bone mineral density in HIV infection and HIV / HCV co-infection;risk factors associated with reduced bone mineral density(BMD); relationship between bone mineral density and reduced liver fibrosis (FE) measured as "liver stiffness" (LS), by FibroScan ® in patients co-infected with HIV / HCV; relationship between reduced bone mineral density and cardiovascular risk assessed with the 10-year Framingham risk score (FRS) in HIV / HCV co-infected Patients And Methods: One hundred and ninety-four HIV-infected subjects (121 males =62% and 73 females = 38 %): 129 HIV-infected ( 66.5 % ) and 65 HIV / HCV co-infe…

osteoporosis Liver diseaseSettore MED/12 - GastroenterologiaSettore MED/09 - Medicina InternaSettore MED/17 - Malattie InfettiveSettore MED/42 - Igiene Generale E ApplicataHIV / HCV co-infected
researchProduct

MALATTIA OSSEA DI PAGET

2010

paget osteoporosis rimodellamento osseoSettore MED/09 - Medicina Interna
researchProduct